Patricia A Escobar
Overview
Explore the profile of Patricia A Escobar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
211
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Reynolds V, Butler P, Abernathy M, Aschenbrenner L, Best D, Blank J, et al.
Regul Toxicol Pharmacol
. 2020 Sep;
117:104746.
PMID: 32911461
Pharmaceutic products designed to perturb the function of epigenetic modulators have been approved by regulatory authorities for treatment of advanced cancer. While the predominant effort in epigenetic drug development continues...
12.
Schoeny R, Cross K, DeMarini D, Elespuru R, Hakura A, Levy D, et al.
Mutat Res Genet Toxicol Environ Mutagen
. 2020 Feb;
849:503137.
PMID: 32087853
The International Workshop on Genotoxicity Testing (IWGT) meets every four years to obtain consensus on unresolved issues associated with genotoxicity testing. At the 2017 IWGT meeting in Tokyo, four sub-groups...
13.
Levy D, Hakura A, Elespuru R, Escobar P, Kato M, Lott J, et al.
Mutat Res Genet Toxicol Environ Mutagen
. 2019 Nov;
848:403075.
PMID: 31708077
The bacterial reverse mutation test is a mainstay for evaluation of mutagenicity predicting the carcinogenic potential of a test substance and is recommended by regulatory agencies across the globe. The...
14.
Williams R, DeMarini D, Stankowski Jr L, Escobar P, Zeiger E, Howe J, et al.
Mutat Res Genet Toxicol Environ Mutagen
. 2019 Nov;
848:503081.
PMID: 31708075
The International Workshop on Genotoxicity Testing (IWGT) meets every four years to seek consensus on difficult or conflicting approaches to genotoxicity testing based upon experience, available data, and analysis techniques....
15.
Levy D, Zeiger E, Escobar P, Hakura A, van der Leede B, Kato M, et al.
Mutat Res Genet Toxicol Environ Mutagen
. 2019 Nov;
848:403074.
PMID: 31708073
A committee was constituted within the International Workshop on Genetic Toxicology Testing (IWGT) to evaluate the current criteria for a valid Ames test and to provide recommendations for interpretation of...
16.
Sasaki J, Allemang A, Bryce S, Custer L, Dearfield K, Dietz Y, et al.
Environ Mol Mutagen
. 2019 Oct;
61(1):114-134.
PMID: 31603995
In May 2017, the Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee hosted a workshop to discuss whether mode of action (MOA) investigation is enhanced through the application of...
17.
Masuda-Herrera M, Dobo K, Kenyon M, Kenny J, Galloway S, Escobar P, et al.
Environ Mol Mutagen
. 2019 Jul;
60(9):766-777.
PMID: 31335992
Arylboronic acids and esters (referred to collectively as arylboronic compounds) are commonly used intermediates in the synthesis of pharmaceuticals but pose a challenge for chemical syntheses because they are often...
18.
Kirkland D, Levy D, LeBaron M, Aardema M, Beevers C, Bhalli J, et al.
Mutat Res Genet Toxicol Environ Mutagen
. 2019 Feb;
839:21-35.
PMID: 30744809
A database of 91 chemicals with published data from both transgenic rodent mutation (TGR) and rodent comet assays has been compiled. The objective was to compare the sensitivity of the...
19.
Dertinger S, Kraynak A, Wheeldon R, Bernacki D, Bryce S, Hall N, et al.
Environ Mol Mutagen
. 2019 Feb;
60(6):513-533.
PMID: 30702769
The in vitro MultiFlow® DNA Damage Assay multiplexes γH2AX, p53, phospho-histone H3, and polyploidization biomarkers into a single flow cytometric analysis. The current report describes a tiered sequential data analysis...
20.
Smith J, Huang Z, Escobar P, Foppiano P, Maw H, Loging W, et al.
Int J Toxicol
. 2017 Nov;
36(6):440-448.
PMID: 29130831
In a previously reported CD-1 mouse 2-year carcinogenicity study with the sodium glucose cotransporter-2 inhibitor empagliflozin, an increased incidence of renal tubular adenomas and carcinomas was identified only in the...